GlaxSmithKline will wait to ramp up manufacturing capacity of its promising malaria vaccine until after it makes its way through the regulatory process.
MIT engineers have developed a new nanoparticle that can protect a vaccine long enough to generate a strong immune response on mucosal surfaces far from the vaccination site.
A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.
Prokarium – a biotech company that was formerly part of UK CMO Cobra Biologics spin-out - has bought an oral vaccine technology from Emergent BioSolutions.
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
Japanese drugmaker Takeda has been awarded JPY24bn ($313m) to develop and a cell culture influenza vaccine and establish a commercial-scale production facility.
US-based vaccine specialist, Caliber Biotherapeutics, has opened the world’s largest modular, plant-made pharmaceutical manufacturing facility at its headquarters in Bryan, Texas.
PPD has added capabilities at the facility acquired from Merck & Co and improved integration of other sites to create its Vaccines & Biologics Center of Excellence, a single provider of multiple laboratory services.
Novavax has completed cGMP scale up of its RSV-F vaccine candidate, with the material being used in preclinical studies, and amended the terms of the H1N1 collaboration with Xcellerex.
Vaccines could be produced in less than 10 weeks from first isolation of the RNA sequence by using insect cell derived influenza VLPs, according to research which has implications for H1N1 and H5N1.
UK biotech firm Acambis has decided to bring the manufacturing of
its soon to be approved smallpox vaccine in-house while its
agreement with contract manufacturer Baxter comes to an end.
